← Leaderboards
Joseph Weinstock
Progenra, Inc.
$1,722,862
Attributed
$1,722,862
Total exposure
2
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $748.9K · FY2014–17$1M$750K$500K$250K$0
'14
'15
'16
'17
Funding mix
By agency
NIH$1,722,862 · 2
By mechanism
R44$1,497,888 · 1
R43$224,974 · 1
Top collaborators
No co-investigators on record.
Most similar at Progenra, Inc.
Same institution · by research overlap
- Kumar Suresh$5,007,499
- Michael R Mattern$5,800,503
- David E Sterner$7,582,782
- Benjamin Nicholson$1,181,002
Others in their field
Top investigators on “In Vivo”
- David Heimbrook · Leidos Biomedical Research, Inc.$371,850,582
- Leonard Freedman · Leidos Biomedical Research, Inc.$304,459,298
- Dennis R. Burton · Scripps Research Institute$212,708,174
- Mark S Klempner · Tufts Medical Center$128,021,180
- Florian Krammer · Icahn School Of Medicine At Mount Sinai$104,723,856
- David M. Margolis · University Of Texas Sw Med Ctr/Dallas$98,374,200
Research focus
In VivoMediatingImmuneIn VitroLeadMalignant NeoplasmsEffector CellGenetic Regulatory ProteinImmunosuppressive AgentsInhibitor/AntagonistIn Vivo ModelKillingsLymph NodesMalignant Neoplasm Of LungCancer TherapyCytotoxicEnzymesEvaluationCell Cycle ProgressionImmunocompetentCell PhysiologyInflammationCellsMesothelioma
Grant awards (3)
Chemical Optimization of a novel class of USP7 inhibitor for cancer treatment$748,944
R44 · FY2017 · CA · contact PI
Chemical Optimization of a novel class of USP7 inhibitor for cancer treatment$748,944
R44 · FY2016 · CA · contact PI
Chemical optimization of a novel class of USP7 inhibitor for cancer treatment$224,974
R43 · FY2014 · CA · contact PI